Zoetis Inc. (NYSE:ZTS) Shares Sold by Pinnacle Wealth Planning Services Inc.

Pinnacle Wealth Planning Services Inc. reduced its stake in Zoetis Inc. (NYSE:ZTS) by 12.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,890 shares of the company’s stock after selling 539 shares during the period. Pinnacle Wealth Planning Services Inc.’s holdings in Zoetis were worth $634,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC increased its holdings in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis during the third quarter valued at about $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis during the third quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the third quarter valued at about $33,000. Finally, Dunhill Financial LLC grew its stake in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Zoetis Price Performance

NYSE ZTS opened at $167.26 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The firm has a market capitalization of $74.90 billion, a PE ratio of 30.58, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The company’s 50 day simple moving average is $166.61 and its 200 day simple moving average is $176.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.20%. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Analysts Set New Price Targets

ZTS has been the subject of several recent analyst reports. Piper Sandler raised their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Leerink Partners initiated coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. StockNews.com cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.